NCT00296829View on ClinicalTrials.gov

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

PHASE2CompletedINTERVENTIONAL

Enrollment

1,080

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Orthomyxoviridae InfectionInfluenzaMyxovirus Infection

Interventions

BIOLOGICAL

Inactivated, split-virion influenza vaccine

Trial Locations (11)

3079

Victoria

3128

Victoria

3144

Victoria

5000

Adelaide

QLD 4152

Carina Heights

QLD 4077

Inala

QLD 4021

Kippa-Ring

NSW 2145

Westmead

Unknown

Auckland

Dunedin

Hamilton

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00296829 - Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly | Biotech Hunter | Biotech Hunter